Medpace: High Order Growth in Clinical Research - Share Price Jump of 16% Towards All-Time High!
Reading Time: 2 minutes
The revenue growth was 17.2% to $707.3 million in the second quarter of 2026. Net new order intake increased by 28.2%, providing the company with a predictable base. The annual forecast for 2026 anticipates total revenue of up to $2.89 billion. Revenue and earnings development in the second quarter On July 22, 2026, Medpace Holdings Inc. (MEDP) released its financial figures for the second quarter. The company recorded revenue of $707.3 million, which represents an increase of 17.2% compared to the same quarter last year. On the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
